0 CHECKOUT

Alcohol Addiction - Pipeline Review, H2 2015

  • ID: 3455176
  • September 2015
  • 141 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Johnson & Johnson
  • MORE

Alcohol Addiction - Pipeline Review, H2 2015

Summary

The report ‘Alcohol Addiction - Pipeline Review, H2 2015’, provides an overview of the Alcohol Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Johnson & Johnson
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Alcohol Addiction Overview

Therapeutics Development

Pipeline Products for Alcohol Addiction - Overview

Pipeline Products for Alcohol Addiction - Comparative Analysis

Alcohol Addiction - Therapeutics under Development by Companies

Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes

Alcohol Addiction - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Alcohol Addiction - Products under Development by Companies

Alcohol Addiction - Products under Investigation by Universities/Institutes

Alcohol Addiction - Companies Involved in Therapeutics Development

AbbVie Inc.

Addex Therapeutics Ltd

Adial Pharmaceuticals, LLC

Arbutus Biopharma Corporation

Astraea Therapeutics, LLC

AstraZeneca Plc

Bionex Pharmaceuticals LLC

Cerecor Inc.

Curemark, LLC

Eli Lilly and Company

Ethypharm S.A.

Euthymics Bioscience, Inc.

Foresee Pharmaceuticals, LLC

H. Lundbeck A/S

Indivior Plc

Johnson & Johnson

Kyorin Pharmaceutical Co., Ltd.

Lohocla Research Corporation

Neurocrine Biosciences, Inc.

Omeros Corporation

Pfizer Inc.

RTI International

SK Biopharmaceuticals Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Tonix Pharmaceuticals Holding Corp.

VM Discovery, Inc.

XenoPort, Inc.

Zynerba Pharmaceuticals, Inc.

Alcohol Addiction - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(disulfiram + selegiline) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(topiramate + ondansetron hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ABT-436 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

amitifadine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

arbaclofen placarbil - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

baclofen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

baclofen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

carisbamate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CM-1212 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Activate HAT for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FP-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

gabapentin enacarbil XR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JDTic - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JNJ-5234801 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LY-2940094 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

odelepran hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-04457845 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

saracatinib difumarate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TKM-ALDH2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

verucerfont - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Alcohol Addiction - Recent Pipeline Updates

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence

Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder

Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting

Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder

Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder

Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro

Nov 26, 2014: Drug recommended to help cut drink dependence

Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder

Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence

Apr 30, 2014: ADial Pharmaceuticals Announces Issuance of First U.S. Patent

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Alcohol Addiction, H2 2015

Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Alcohol Addiction - Pipeline by AbbVie Inc., H2 2015

Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015

Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2015

Alcohol Addiction - Pipeline by Arbutus Biopharma Corporation, H2 2015

Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2015

Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2015

Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2015

Alcohol Addiction - Pipeline by Cerecor Inc., H2 2015

Alcohol Addiction - Pipeline by Curemark, LLC, H2 2015

Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2015

Alcohol Addiction - Pipeline by Ethypharm S.A., H2 2015

Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2015

Alcohol Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015

Alcohol Addiction - Pipeline by H. Lundbeck A/S, H2 2015

Alcohol Addiction - Pipeline by Indivior Plc, H2 2015

Alcohol Addiction - Pipeline by Johnson & Johnson, H2 2015

Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015

Alcohol Addiction - Pipeline by Lohocla Research Corporation, H2 2015

Alcohol Addiction - Pipeline by Neurocrine Biosciences, Inc., H2 2015

Alcohol Addiction - Pipeline by Omeros Corporation, H2 2015

Alcohol Addiction - Pipeline by Pfizer Inc., H2 2015

Alcohol Addiction - Pipeline by RTI International, H2 2015

Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015

Alcohol Addiction - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015

Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015

Alcohol Addiction - Pipeline by VM Discovery, Inc., H2 2015

Alcohol Addiction - Pipeline by XenoPort, Inc., H2 2015

Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Alcohol Addiction Therapeutics - Recent Pipeline Updates, H2 2015

Alcohol Addiction - Dormant Projects, H2 2015

Alcohol Addiction - Dormant Projects (Contd..1), H2 2015

Alcohol Addiction - Dormant Projects (Contd..2), H2 2015

Alcohol Addiction - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Alcohol Addiction, H2 2015

Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Arbutus Biopharma Corporation
Astraea Therapeutics, LLC
AstraZeneca Plc
Bionex Pharmaceuticals LLC
Cerecor Inc.
Curemark, LLC
Eli Lilly and Company
Ethypharm S.A.
Euthymics Bioscience, Inc.
Foresee Pharmaceuticals, LLC
H. Lundbeck A/S
Indivior Plc
Johnson & Johnson
Kyorin Pharmaceutical Co., Ltd.
Lohocla Research Corporation
Neurocrine Biosciences, Inc.
Omeros Corporation
Pfizer Inc.
RTI International
SK Biopharmaceuticals Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.